key: cord-0956179-19l584gx
authors: Fike, Alice; Hartman, Julia; Redmond, Christopher; Williams, Sandra G.; Ruiz‐Perdomo, Yanira; Chu, Jun; Hasni, Sarfaraz; Ward, Michael M.; Katz, James D.; Gourh, Pravitt
title: Risk factors for COVID‐19 and rheumatic disease flare in a US cohort of Latino patients
date: 2021-01-17
journal: Arthritis Rheumatol
DOI: 10.1002/art.41656
sha: 5439cb26eaa0ceec94fdbe11d8de3cb118ab142e
doc_id: 956179
cord_uid: 19l584gx

OBJECTIVES: Latino patients are overrepresented among cases of coronavirus disease 2019 (COVID‐19) and are at an increased risk for severe disease. Prevalence of COVID‐19 in Latinos with rheumatic diseases are poorly reported. The purpose of this study was to characterize COVID‐19 clinical features and outcomes in Latino patients with rheumatic diseases. METHODS: This is a retrospective study of Latino patients with rheumatic diseases from an existing observational cohort in the Washington, DC area. Patients seen between April 1 to October 15, 2020 were analyzed in this study. We reviewed demographics, body mass index (BMI), comorbidities, and immunomodulatory therapies. An exploratory Classification and Regression Tree (CART) analysis along with logistic regression (LR) analyses were performed to identify risk factors for COVID‐19 and rheumatic disease flare. RESULTS: Out of 178 patients, 32 (18%) were identified with COVID‐19 and the incidence rate of infection was found to be three‐fold higher than the general Latino population. No patients required ICU level care. CART analysis and multivariable LR analysis identified BMI>30.35 as a risk factor for COVID‐19 [P=0.004, OR=3.37, 95%CI (1.5‐7.7)]. COVID‐19 positivity was a risk factor for rheumatic disease flare [P=0.02, OR=4.57, 95%CI (1.2‐17.4)]. CONCLUSION: Latino patients with rheumatic diseases had a higher rate of COVID‐19 compared with the general Latino population. Obesity was identified as a risk factor for COVID‐19 and COVID‐19 itself was found to be a risk factor for rheumatic disease flare. Latino patients with risk factors should be followed closely, especially post‐COVID‐19 in anticipation of disease flare.

with rheumatic diseases could especially be at risk for complications from COVID-19 due to immune system dysfunction and concomitant use of immunomodulatory therapies. However, evidence on outcomes of COVID-19 in patients with rheumatic diseases has been conflicting thus far. Initial reports (8) revealed no unique or outstanding risk factors, apart from what has already been noted in the general population. An Italian study indicated a possible increased incidence of COVID-19 in patients with rheumatic diseases (9) .

Studies on COVID-19 in patients with rheumatic diseases have focused on risk factors for morbidity and mortality directly attributable to SARS-CoV-2 infection. The potential effects of COVID-19 on the trajectory of the underlying rheumatic diseases have not been characterized. Infectious agents have been proposed as an environmental trigger for autoimmunity and viral infections are a known trigger for rheumatic disease flares.

Therefore, it may be anticipated that patients with rheumatic disease and SARS-CoV-2 infection would be at a higher subsequent risk for a flare of the baseline rheumatic disease.

Latinos represent the largest and fastest growing minority population in the United States. Latinos living in the United States not only have a higher prevalence of obesity, diabetes, and kidney diseases, but also have lower rates of insurance coverage than the general population (10, 11) . Latinos are more likely to work in positions considered to be essential thus increasing their risk for exposure to infections (12) . Such jobs often provide limited or no sick time, further perpetuating this increased risk to Latino workers (13) . The combination of these factors has led to Latino patients being disproportionately impacted by COVID-19, resulting in increased incidence, severity of disease and mortality (1, (3) (4) (5) .

This article is protected by copyright. All rights reserved At the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) rheumatology clinic, we follow a diverse cohort of patients with rheumatic diseases, the majority of whom are Latino women. These patients have a representative mix of autoimmune diseases typically seen in outpatient settings with most patients receiving immunomodulatory therapy. Given the importance of understanding the risk of COVID-19 in Latino patients with rheumatic diseases, we investigated for risk factors increasing risk for SARS-CoV-2 infection and subsequent rheumatic disease flare.

Study Cohort: All patients were consented and were participants of an institutional review board-approved natural history study in the Intramural Research Program at NIAMS.

The patients were part of an observational cohort with 307 active participants with rheumatic diseases who were referred to our clinic primarily from federally qualified health centers in the local area. All participants were contacted from April 1, 2020 to June 1, 2020 by phone and made aware of COVID-19 symptoms and informed of the steps to follow in case of exposure or infection to SARS-CoV-2. Patients were further assessed for COVID-19 symptoms or exposure prior to each in-person contact (i.e., lab testing or clinic visit) as well as during each virtual clinic appointment. During the study period from April 1, 2020 to October 15, 2020, we identified 32 patients with COVID-19 and all of them were of selfreported Latino ethnicity. No non-Latino patients reported COVID-19 infection during the study period (n=81). Latino patients seen during the study period, who were asymptomatic for COVID-19 and denied exposure (but not tested for COVID-19) were selected as a comparator group (n=146).

SARS-CoV-2 viral RNA real-time polymerase-chain-reaction (RT-PCR) test or the presence of anti-SARS-CoV-2 antibodies. Antibodies to SARS-CoV-2 were detected using the Elecsys

This article is protected by copyright. All rights reserved anti-SARS-CoV-2 from Roche Diagnostics. Given the difficulty in obtaining RT-PCR testing to detect SARS-CoV-2 during the early phases of the pandemic, we also included one patient with COVID-19-like symptoms who was not tested but had a close household contact with COVID-19 (Table 1) .

This was a retrospective study design utilizing an existing observational cohort. The following variables were recorded: demographics, rheumatic disease type, disease flare, body mass index (BMI) measurement along with comorbidities (hypertension, diabetes mellitus, previous lung disease), current immunomodulatory treatment, changes to immunomodulatory treatment, glucocorticoids in milligrams used pre-and post-infection, and mortality. For SARS-CoV-2 positive patients, we also report COVID-19 manifestations, management, and hospitalization course. Due to the heterogeneous nature of the cohort, rheumatic disease flare was defined as any escalation of immunomodulatory therapy. COVID-19 incidence rate for Latino residents of the local area was calculated using the local health department case counts as the numerator (14) and the census data (15) as the denominator and reported as a range of the cases reported by the counties and municipalities comprising the area. 

This article is protected by copyright. All rights reserved covariates was performed. CART results were analyzed using a two-tailed Mid-P exact test.

Multivariate LR analyses were performed to identify risk factors for COVID-19 and rheumatic disease flare (SAS 9.4). Univariate LR analysis using various immunomodulatory treatments were performed to identify risk factors for COVID-19.

Patient population: A total of 178 Latino patients with rheumatic diseases were included in our analysis. Thirty-two patients were diagnosed with COVID-19 who were predominantly female (91%) with a mean age of 46 years and were similar to the COVID-19 negative group ( Table 1 ). All of the COVID-19 patients were either essential workers themselves or lived in an essential worker household. The majority were uninsured (25/32; 78.2%). None of the COVID-19 patients were smokers. Mean BMI of the COVID-19 patients was higher as compared to the COVID-19 negative group (32.5 vs 29.7) ( Table 1) .

Prevalence of hypertension, diabetes mellitus, and previous lung disease were similar between the two groups. All but two patients were receiving immunomodulatory treatment at the time of COVID-19 diagnosis. Immunomodulatory medications were held in (14/30; 46.6%) patients peri-infectiously. The COVID-19 incidence rate for our cohort was 17,978/100,000, which was 3-fold higher than the 4,689 to 5,809/100,000 incidence rate observed in the Latino residents and 5-to 11-fold higher than the 1,540 to 3,431/100,000 for the general population, both within the local catchment areas, during the study period.

Clinical symptoms and management of patients with rheumatic diseases and COVID-19: All patients reported with COVID-19 developed symptoms, with cough and fever present in 66% ( Figure 1A ). SARS-CoV-2 infection was confirmed by RT-PCR in 25 out of 26 patients and five of the remaining six patients were found to have antibodies to SARS-CoV-2 (Table 1) . One individual could not obtain RT-PCR testing and received subsequent negative antibody testing four months later but had classic COVID-19 symptoms and a COVID-19 positive household contact. Most patients (81%) required only outpatient

This article is protected by copyright. All rights reserved treatment for their COVID-19 ( Figure 1B) . Two of the six hospitalized patients required supplemental oxygen and have since recovered completely. No patients required ICU admission and no deaths were reported in this cohort.

The most common rheumatic disease treatment category was conventional disease modifying antirheumatic drugs (cDMARDs, Table 1 , Figures 1C, 1D) . COVID-19 positive patients had lower glucocorticoids (GCs) usage (21.8%) with a higher mean daily dose (7.4 mg, Table 1 ).

In COVID-19 patients, 75% were being treated with hydroxychloroquine whereas 40.6%

were being treated with biologics or small molecular inhibitor therapeutics (Table 1 , Figures   1C, 1D ).

we wanted to explore risk factors for COVID-19. CART analysis identified BMI>30.35 as the main COVID-19 risk factor observed in 62.5% of patients (P=0.004, Figure 2A ). Among the non-obese patients, age>39.5 was identified as the risk factor. As an alternative approach, we performed a multivariable LR analysis using all the above variables and identified BMI as a risk factor for COVID-19 [OR 3.37 (95%CI 1.5-7.7) for BMI>30.35 versus BMI<30.35, P=0.004, Figure 2C ].

We then examined the role of a specific therapeutic agent increasing susceptibility for COVID-19. Univariate LR analysis of each immunomodulatory therapy was performed to identify risk factors for COVID-19 ( Figure 2E ). None of the immunomodulatory therapies demonstrated any statistically significant susceptibility or protection for COVID-19.

Following COVID-19, twenty-seven (84%) patients were evaluated in clinic and eight were found to have a rheumatic disease flare. The median oral GC dose increased from 0 mg to 12.5 mg daily.

This article is protected by copyright. All rights reserved Persistent symptoms attributable to COVID-19 were seen in ten patients (31.2%) (anosmia-3, new generalized alopecia-3, new or worsened headaches-2, new peripheral neuropathy-1, weight loss>10% due to anorexia-1).

Of the eight patients with disease flare and COVID-19, two were in sustained remission and off immunomodulatory therapy, two had their therapy withheld, and the remaining four had no interruptions in therapy. Next, we explored the risk accorded by COVID-19 positivity and interruptions in immunomodulatory therapy in causing flares. CART analysis identified COVID-19 positivity as a risk factor for disease flares (P=0.0007, Figure   2B ). In COVID-19 negative patients, interruptions in immunomodulatory therapy were identified as a risk factor for disease flares (P=0.00003, Figure 2B ). A multivariate LR analysis also identified COVID-19 positivity as a risk factor for disease flare [OR 4.57 (95%CI 1.2-17.4), P=0.02, Figure 2D ].

We have a unique cohort of Latino patients with established rheumatic diseases who are essential workers or living with essential workers and at the forefront of the COVID-19 pandemic. In our cohort, Latino patients with rheumatic diseases had a higher incidence of COVID-19 as compared to Latino residents within our geographical region; but none had a poor outcome. We identified obesity and increasing age as risk factors for COVID-19. The 

This article is protected by copyright. All rights reserved Strengths of our study include a longitudinal, well-established Latino patient cohort, reducing referral bias. Our study allowed for self-reporting of infection thus reducing the selection bias towards enrollment of sicker patients as seen in previous reports of in Latino patients. We captured a representative sample of our cohort (79%) with 178 of 226 Latino participants being assessed during the study period.

Despite these strengths, there are important limitations to this study. This was a retrospective, observational study from a single site, thus limiting generalizability of the findings. Our cohort patients and their family members represent essential and frontline workers, who were at an increased risk of exposure to SARS-CoV-2 and this could have led to a selection bias. Surveillance bias due to increased awareness and testing of our patients because of their rheumatic diseases and immunosuppression could have led to increased identification of COVID-19 in our cohort. A recent publication from Italy observed a similar increase in prevalence of COVID-19 in patients with systemic autoimmune diseases (9) .

Smoking may be a confounder and was not assessed in this study. None of the COVID-19 positive patients were smokers and thus we could not use this variable in our multivariate analysis. We did have previous lung disease as a covariate which could potentially capture some effects of smoking (both active and passive). Further, we did not assess for community exposure duration or the level of community spread specific to individual patients and risk of exposure was likely influenced by these factors which we could not capture in our analyses.

In this study of Latino patients with rheumatic diseases, a higher prevalence of COVID-19 was observed; with obesity identified as a risk factor. COVID-19 positivity was identified as a risk factor for rheumatic disease flare. COVID-19 infection-related poor outcomes were not observed but persistent COVID-19 symptoms were reported. Future studies including marginalized populations, with larger sample sizes from different geographic locations, including younger patients, and with longer follow-up periods are warranted to confirm these findings. Tables & Figures-Table 1 Characteristics of the patients with rheumatic diseases by COVID-19 status 

Coronavirus Disease 2019 Case Surveillance -United States

Hospitalization and Mortality among Black Patients and White Patients with Covid-19

Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California

Characteristics and clinical outcomes of COVID-19 in

Hispanic/Latino patients in a community setting: A retrospective cohort study

Prevalence and Severity of Coronavirus Disease 2019 (COVID-19) Illness in Symptomatic Pregnant and Postpartum Women Stratified by Hispanic Ethnicity

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries

COVID-19 in Italian patients with rheumatic autoimmune systemic diseases

Tables of Summary Health Statistics for the

Prevalence of diabetes among Hispanics/Latinos from diverse backgrounds: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

Racial and Ethnic Differentials in COVID-19-Related Job Exposures by Occupational Status in the US. medRxiv

Paid sick leave benefits, influenza vaccination, and taking sick days due to influenza-like illness among U.S. workers. Vaccine

District of Columbia COVID-19 Surveillance data

Accepted Article